Article
Chronic lymphocytic leukemia treatment algorithm 2022.
Blood cancer journal - 29 Nov 2022
Hampel Paul J, Parikh Sameer A
Abstract excerpt
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton tyrosine kinase inhibitors and venetoclax) and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
